_	_ <u>Day 1 - 17 JUNE 2010</u>				
	08:30 - 08:40	Welcome & Introduction	EBF		
	08:40 - 09:10	Plenary session	Philip Timmerman (J&J, EBF)		
	09:10 - 10:50	DBS in the non regulated environment Session			
	09:10 - 09:30 09:30 - 09:45	K. Beaumont (Pfizer) F. Picard (Novartis)	Who decided we should measure plasma? "An overview of the implementation of Dried Blood Spots (DBS) at Novartis: results and next step" Dried Blood Spots for Metabolite Identification: Con-		
	09:45 - 10:00	P. Wright (Pfizer)	Dried Blood Spots for Metabolite Identification: Can we? Should we?		
	10:15 - 11:30	C. Smith (AstraZeneca)	Metabolite profiles from Dried Biofluid Spots for Metabonomic studies using UPLC combined with oaTOF-MS		
	10:30 - 10:50	panel discussion			
	10:50 - 11:20	Break			
	11:20 - 12:30	Combined Poster and tutorial tutorial 1 Sampling from small animals (moderator identified)			
		tutorial 2	Practical aspects of spotting on cards (moderator identified)		
		tutorial 3	Instrumental aspects of card punching (moderator identified)		
		tutorial 4	Sampling in the clinic or in phase 3 trials		
		tutorial 5	Logistics and regulatory aspects of shipping of cards		
	12:30 - 13:30	Lunch			
	13:30 - 15:30	Combined Tox/regulatory/QA Session			
	13:30 - 13:50	TOX F. McClure (GSK)	Spot the Difference – effect of TK blood sampling on Clinical Pathology parameters		
	13:50 - 14:05	L. Patrone (BMS)	Direct Comparison of Dried Blood Spot (DBS) Analysis to Plasma and Whole Blood Analysis in Toxicokinetic Studies of Rats		
:	14:05 - 14:20	Speaker to be identified			
	14:20 - 14:35	J. Burnett (Covance)	Practical Application of Dried Blood Spot Techniques in Toxicology		
		REG/QA			

14:35 - 15:10	M. Benton (Fulcrum Pharma)	QA perspective on Dried Blood Spot analysis
15:10 - 15:30	panel discussion	
15:30 - 16:00	Break	
16:00 -18:00	Bioanalytical and DBS:	applications
16:00 - 16:20	P. Abu-Rabie (GSK)	Direct quantitative bioanalysis of drugs in dried blood spot samples
16:20 - 16:40	H. Ghobarah (AB Sciex)	High Sensitivity LC/MS/MS Quantification of Corticosteroids in Dried Blood Spots and Evaluation of Software Saturation Correction for Extending Dynamic Range
16:40 - 17:00	M. Barfield (GSK)	The use of Dried Plasma Spots (DPS) and Dried Urine Spots (DUS) for LC/MS/MS assays
17:00 - 17:20	A. Gajate Perez (Roche)	Can Dried Blood Spot technique be used to stabilize ester pro-drugs and glucuronide metabolites?
17:20 - 17:40	L. Goodwin (Covance)	Quantitative Determination of a Therapeutic Peptide in Dried Blood Spots
17:40 - 18:00	panel discussion	
18:00 - 19:00	Complementary cockta	il reception

Day 2 - 18 JUNE 2010				
08:30 - 10:00	Clinical Session			
08:30 - 08:50	A. Van Peer (J&J)	Blood and plasma: a magic twin in pharmacokinetics?		
08:50 - 09:05	HC Pandya (Univ. of Leicester)	PK studies in Infants and Children: are dried blood spots the answer?		
09:05 - 09:20	L. Stolk (Univ. Maastricht)	Dried blood spot methods in therapeutic drug monitoring: methods, assays and pitfalls		
09:20 - 09:40	T. de Boer (Xendo)	Extensive utilisation of Dried Blood Spot sampling in early clinical development studies: pharmacokinetics, pharmacogenomics and safety assessments		
09:40 - 10:00	panel discussion			
10:00 - 10:30	Break			
- 10:30 - 11:30	Bioanalytical and DBS: tools			
-	-			

10:30 - 10:50	B. Ooms (Spark	on-line DBS-SPE-MS/MS - feasibility of a concept	
	Holland)	for rapid DBS analysis without punching	
10:50 - 11:10	G. Harland (Waters)	The Use of an Integrated Micro Fluidic LC/MS/MS Device for DBS Assays an Approach to Increased Sensitivity	
11:10 - 11:30	J. Dinan (BSD Robotics)	BSD robotics: bringing the DBS advantage into the Laboratory	
11:30 - 12:30	Lunch		
12:30 - 13:30	breakouts/discipline		
	in preparation of panel discussion	DBS and discovery/non regulated environment	
	2 moderators	DBS and toxicology	
		DBS in the clinic	
		Bioanalytical challenges for DBS	
13:30 - 14:30	Breakout FB - Panel Discussion and conclusion		
	5 min comments/feedback from each break out final panel discussion conclusion of the meeting		
14:30	adjourn		